| Literature DB >> 32591538 |
Johannes Karges1, Shi Kuang2, Federica Maschietto3, Olivier Blacque4, Ilaria Ciofini3, Hui Chao5, Gilles Gasser6.
Abstract
The use of photodynamic therapy (PDT) against cancer has received increasing attention over recent years. However, the application of the currently approved photosensitizers (PSs) is limited by their poor aqueous solubility, aggregation, photobleaching and slow clearance from the body. To overcome these limitations, there is a need for the development of new classes of PSs withEntities:
Mesh:
Substances:
Year: 2020 PMID: 32591538 PMCID: PMC7320011 DOI: 10.1038/s41467-020-16993-0
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919
Fig. 1Chemical structures of complexes 1–7 investigated in this study.
The complexes were isolated as hexafluorophosphate salts.
Spectroscopic properties and singlet oxygen quantum yields in acetonitrile and aqueous solution.
| Spectroscopic properties | Singlet oxygen quantum yield/% | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| σ2/GM | Direct | Direct 450 nm D2O | Indirect | Indirect | Indirect | Indirect | ||||||
| 300 (81.6), 385 (111.6), 515 (47.8) | 147 | 677 | 1.9 | 86 | 385 | 65 | n.d. | 66 | 5 | 61 | 3 | |
| 305 (109.5), 425 (133.4), 495 (111.8) | 2175 | 709 | >0.1 | 48 | 222 | 18 | n.d. | 25 | 3 | 16 | 1 | |
| 305 (96.6), 370 (152.3), 495 (63.9) | 573 | 682 | 1.1 | 76 | 338 | 52 | n.d. | 48 | 6 | 49 | 5 | |
| 290 (57.0), 425 (93.5), 485 (82.6) | 838 | 703 | 0.4 | 69 | 417 | 34 | n.d. | 40 | 2 | 37 | 3 | |
| 295 (76.9), 360 (99.8), 475 (39.5) | 313 | 674 | 1.4 | 36 | 231 | 54 | n.d. | 51 | 8 | 46 | 6 | |
| 290 (79.0), 415 (57.3), 460 (61.4) | 349 | 697 | 0.5 | 54 | 405 | 46 | n.d. | 53 | 2 | 38 | 2 | |
| 290 (95.7), 365 (64.8), 465 (34.4) | 263 | 664 | 2.8 | 96 | 542 | 75 | n.d. | 77 | 11 | 68 | 10 | |
Average of three independent measurements.
λabs absorption maximum, σ2 2P absorption cross section, λem emission maximum, Φem luminescence quantum yield, τ excited state lifetime, n.d. not detectable.
Fig. 2Absorption spectra of the complexes 1–7.
a 1P absorption spectrum in acetonitrile and b 2P absorption spectrum in dichloromethane.
Fig. 3Tumor growth inhibition assay in HeLa MCTS.
Change of the volume in MCTS in correlation to the time of the treatment. The MCTS were treated with compounds 1–7 (20 μM, 2% DMSO, v%), H2TPP (20 μM, 2% DMSO, v%), and cisplatin (10 μM and 30 μM). The MCTS were a strictly kept in the dark, b exposed to 1P irradiation (500 nm, 16.7 min, 10.0 mW cm−2, and 10 J cm−2), c exposed to 2P irradiation (800 nm, 10 J cm−2 with a section interval of 5 μm) on day 3. The error bars correspond to the standard deviation of the three replicates.
Fig. 4Representative image of the cell viability assay in HeLa MCTS.
MCTS were treated with compounds 1–7 (20 μM, 2% DMSO, v%) in the dark for 3 days. After this time, MCTS were kept in the dark, exposed to 1P irradiation (500 nm, 16.7 min, 10.0 mW cm−2, and 10 J cm−2) or 2P irradiation (800 nm, 10 J cm−2, and section interval of 5 μm). After 2 days, the cell viability was assessed by measurement of the fluorescence of calcein (λex = 495 nm, λem = 515 nm), which is generated in living cells from Calcein AM. The scale bar represents a length of 200 µm.
Fig. 5Biological Evaluation of 7 inside a mouse model.
In vivo PDT study of 7 using 1P (500 nm, 60 min, 10.0 mW cm−2, and 36 J cm−2) or 2P (800 nm, 50 mW, 1 kHz, pulse width 35 fs, and 5 s mm−1) excitation on nude mice bearing a doxorubicin-selected P-gp-overexpressing human colon cancer tumor (SW620/AD300). a Tumor growth inhibition curves upon treatment. b Average body weights of the tumor-bearing mice. c Representative photographs of the tumor-bearing mice. The error bars correspond to the standard deviation of the five replicates.